Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

Journal of Psychopharmacology

Volumn 23, Issue 4, 2009, Pages 419-427

  Jasinski, D R ^a   Krishnan, S S ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Formerly of New River Pharmaceuticals Inc   (United States)

Author keywords

Abuse; ADHD; LDX; Lisdexamfetamine; Stimulant; Vyvanse

Indexed keywords

AMFEPRAMONE; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; LISDEXAMFETAMINE; UNCLASSIFIED DRUG; VYNANSE;

ADDICTION RESEARCH CENTER INVENTORY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ABUSE; DRUG CHOICE; DRUG EFFECT; DRUG RATING QUESTIONNAIRE SUBJECT; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; MALE; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SINGLE DRUG DOSE; STREET VALUE ASSESSMENT QUESTIONNAIRE; TREATMENT ENJOYMENT ASSESSMENT QUESTIONNAIRE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DIETHYLPROPION; FEMALE; HEART RATE; HUMANS; MALE; PRODRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 65649122238     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109103113     Document Type: Article

References (18)

1. American Academy of Child and Adolescent Psychiatry (2007) Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 47: 894 - 921.
2. American Academy of Pediatrics Subcommittee on Attention-Deficit/ Hyperactivity Disorder Committee on Quality Improvement (2001) Clinical practice guideline: treatment of the school-aged child with attention-deficit/ hyperactivity disorder. Pediatrics 108: 1033 - 1044.
3. Biederman J, Boellner SW, Childress A, Lopez FA, Krishnan S, Zhang Y, (2007a) Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: a double-blind, placebo-controlled, crossover analog classroom study. Biol Psychiatry 62: 970 - 976.
4. Biederman J, Faraone SV, (2005) Attention-deficit hyperactivity disorder. Lancet 366: 237 - 248.
5. Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL, (2007b) Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther 29: 450 - 463.
6. Folstein MF, Folstein SE, McHugh PR, (1975) "Mini-mental stateg". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189 - 198.
7. Jasinski D, Krishnan S, (2006) Pharmacokinetics of oral lisdexamfetamine dimesylate (LDX; NRP104) vs d-amphetamine in healthy adults with a history of stimulant abuse. Poster presented at: US Psychiatric and Mental Health 19th Annual Congress; November 15-19, 2006; New Orleans, LA.
8. Jasinski DR, (2000) An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 14: 53 - 60.
9. Jasinski DR, Kovacevic-Ristanovic R, (2000) Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 23: 149 - 156.
10. Jasinski DR, Krishnan S, (2006) Abuse liability of intravenous L-lysine-d-amphetamine (NRP104). Presented at: College on Problems of Drug Dependence 68th Annual Scientific Meeting; June 17-22, 2006; Scottsdale, AZ. Abstract 365.
11. Jasinski DR, Nutt JG, Griffith JD, (1974) Effects of diethylpropion and d-amphetamine after subcutaneous and oral administration. Clin Pharmacol Ther 16: 645 - 652.
12. Krishnan S, Jasinski D, (2006) Pharmacokinetics of oral NRP104/SPD489 (lisdexamfetamine dimesylate) versus d-amphetamine in healthy adults with a history of stimulant abuse. Abstract presented at: The College on Problems of Drug Dependence 68th Annual Meeting; June 17-22, 2006; Scottsdale, AZ.
13. Martin WR, Sloan JW, Sapira JD, Jasinski DR, (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12: 245 - 258.
14. Pliszka SR, Crismon ML, Hughes CW, Conners CK, Emslie GJ, Jensen PS, ; Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention-Deficit/Hyperactivity Disorder, et al. (2006) The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45: 642 - 657.
15. Schuster CR, (2006) History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 83 (Suppl. 1). S8 - S14.
16. Shojaei A, Ermer JC, Krishnan S, (2007) Lisdexamfetamine dimesylate as a treatment for ADHD: dosage formulation and pH effects. Poster presented at: the 160th Annual Meeting of the American Psychiatric Association; May 19-24, 2007; San Diego, CA. Poster NR 740.
17. Volkow ND, Swanson JM, (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160: 1909 - 1918.
18. Wigal SB, Kollins SH, Squires LA, Childress AC, Lisdexamfetamine dimesylate demonstrated efficacy throughout the day up to 13 hours in an analog classroom study in children with attention-deficit/hyperactivity disorder. Poster presented at: The American Academy of Child & Adolescent Psychiatry's 55th Annual Meeting; October 28-November 2, 2008; Chicago, IL.